AR035163A1 - Compuesto derivado de n-fenil-2-hidroxi-2-metil-3,3,3-trifluoropropanamida, composicion farmaceutica, uso en la fabricacion de un medicamento y proceso para su preparacion - Google Patents
Compuesto derivado de n-fenil-2-hidroxi-2-metil-3,3,3-trifluoropropanamida, composicion farmaceutica, uso en la fabricacion de un medicamento y proceso para su preparacionInfo
- Publication number
- AR035163A1 AR035163A1 ARP000104623A ARP000104623A AR035163A1 AR 035163 A1 AR035163 A1 AR 035163A1 AR P000104623 A ARP000104623 A AR P000104623A AR P000104623 A ARP000104623 A AR P000104623A AR 035163 A1 AR035163 A1 AR 035163A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- carbon
- nitrogen
- ring
- hydroxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 11
- 229910052799 carbon Inorganic materials 0.000 abstract 11
- 229910052757 nitrogen Inorganic materials 0.000 abstract 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- -1 nitro, hydroxy, amino Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- JHSBXNFXGVSVQO-UHFFFAOYSA-N 3,3,3-trifluoro-2-hydroxy-2-methyl-n-phenylpropanamide Chemical compound FC(F)(F)C(O)(C)C(=O)NC1=CC=CC=C1 JHSBXNFXGVSVQO-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/42—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Un compuesto derivado de N-fenil-2-hidroxi-2-metil-3,3,3-trifluoropropanamida que tiene la fórmula (1): donde n es 1 ó 2; R1 es cloro, fluoro, bromo, metilo o metoxi; R2 se selecciona entre uno de los siguientes tres grupos: i) halo, nitro, hidroxi, amino o ciano; ii) - X1 -R5 donde X1 es un enlace directo -O-, -S-, -SO-, -SO2-, NR6-, -CO-, - CONR6 -, -NR6CO-, -NR6SO2- o NR6CONR7-; donde R6 y R7 son independientemente hidrógeno o C1-4alquilo opcionalmente sustituído con uno o más A; y R5 se selecciona entre C1-6 alquilo opcionalmente sustituído con uno o más A, C3-7 cicloalquilo opcionalmente sustituído con uno o más A, C3-7 cicloalquil C1-6 alquilo opcionalmente sustituído con uno o más A, C2-6 alquenilo opcionalmente sustituído con uno o más A, C2-6 alquinilo opcionalmente sustituído con uno o más A, fenilo opcionalmente sustituído con uno o más D, fenilC1-6 alquilo opcionalmente sustituído con uno o más D, anillo heteroarilo opcionalmente sustituído en un carbono del aniloo por uno o más D o (anilo heteroarilo)C1-6 alquilo opcionalmente sustituído en un carbono del anillo con uno o más D; donde dicho anillo heteroarilo es un anillo de 6 miembros unido al carbono que contiene 1-2 átomos de nitrógeno o un anillo de 5 miembros unido al carbono que contiene 1-3 heteroátomos seleccionados independientemente entre O,N y S; y donde si dicho anillo heteroarilo de cinco miembros contiene una porción -NH- dicho nitrógeno puede ser opcionalmente sustituído con un grupo seleccionado de G; iii) un grupo heterocíclico de 4-8 miembros unido al nitrógeno, opcionalmente sustituído en un carbono del anillo por uno o más D y donde si dicho grupo heterociclico contiene una porción -NH- dicho nitrógeno puede ser opcionalmente sustituído con kun grupo seleccionado de G; R3 es C1-6alquilo opcionalmente sustituído con uno o más A, C3-7cicloalquilo opcionalmente sustituído con uno o más A, fenilo opcionalmente sustituído con uno o más D, anillo heteroarilo de 6 miembros unido al carbono que contiene 1 ó 2 átomos de nitrógeno opcionalmente sustituídos en un carbono del anillo por uno o más D, o anillo heteroarilo de 5 miembros unido al carbono que contiene 1-3 heteroátomos seleccionados independientemente entre O;N y S opcionalmente sustituídos en un carbono del anillo por uno o más D y donde si dicho anillo heteroarilo de 5 miembros contiene una porción -NH- dicho nitrógeno puede ser opcionalmente sustituído con un grupo seleccionado de G; A se selecciona entre hidroxi, amino, halo, carboxi, N-(C1-4alquil)amino, N,N-di-(C1-4alquil)amino, carbamoilo y C1-6alcoxi; D se selecciona entre: i) -Xa-Rc donde Xa es un enlace directo, -O-, -S-, -SO-, -O2- -CO-, -NRdSO2-, - NRdCO-, -NRdCONRe-, -NRd o -CONRd, donde Rd y Re son independientemente hidrógeno o C1-4alquilo opcionalmente sustituído con uno o más hidroxi o C1-4alcoxi; y Rc se selecciona entre hidrógeno o C1-6alquilo opcionalmente sustituído con uno o más hidroxi o C1-4alcoxi; ii) un Het de 4 a 8 miembros el cual es opcionalmente sustituído en un carbono del anillo con uno o más grupos seleccionados entre hidroxi, halo, C1-4alcoxi, C1-4alquilo o ciano y donde si dicho Het de 4-8 miembros contiene una porción -NH- dicho nitrógeno puede ser opcionalmente sustituído con kun grupo seleccionado de G; iii) -Xa-C1-6alquil-Xb-Rc donde Xa y Rc con como se definió anteriormente y Xb es -S-, -SO- o -SO2-; iv) ciano o halo; y v) -Xc-Rf en donde Xc es -C(O)- o -SO2- y Rf es un gkrupo heterocíclico de 4-8 miembros unido al nitrógeno opcionalmente sustituído en un carbono del anillo por uno o más grupós seleccionados entre hidroxi, halo, C1-4alcoxi, C1-4alquilo o ciano y donde si dicho grupo heterrocíclico contiene una porción -NH- dicho nitrógeno puede ser opcionalmente sustituído con un grupo seleccionado de G; G se selecciona entre C1-6alquilo opcionalmente sustituído con uno o más A, C1-6alcanoilo opcionalmente sustituído con kluno o más A, C1-6 alquilsulfonilo opcionalmente sustituído con uno o más A, C1-6alcoxicarbonilo opcionalmente sustituído con uno o más A, carbamoilo, N-(C1-6alquil) y carbamoilo opcionalmente sustituído con uno o más A, N-(C1-6alquil)2carbamoilo opcionalmente sustituído con uno o más A y benzoilo opcionalmente sustituído con uno o más A; y R4 es hidrógeno o fluoro; o una sal aceptable para uso farmacéutico o un éster hidrolizable in vivo del mismo. Además se describen composiciones farmacéuticas, usos y procesos para la preparación de compuestos de la fórmula (I). Estos compuestos elevan la actividad de piruvato deshidrogenasa (PDH), y por lo tanto son útiles en el tratamiento de estados de enfermedad asociados con la actividad reducida de la PDH en particular el tratamiento de diabetes mellitus, enfermedad vascular periférica e isquemia del miocardio en animales de sangre caliente tales como humanos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9920814.2A GB9920814D0 (en) | 1999-09-04 | 1999-09-04 | Chemical compounds |
| GB0006641A GB0006641D0 (en) | 2000-03-21 | 2000-03-21 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035163A1 true AR035163A1 (es) | 2004-05-05 |
Family
ID=26243905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104623A AR035163A1 (es) | 1999-09-04 | 2000-09-04 | Compuesto derivado de n-fenil-2-hidroxi-2-metil-3,3,3-trifluoropropanamida, composicion farmaceutica, uso en la fabricacion de un medicamento y proceso para su preparacion |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6689909B1 (es) |
| EP (1) | EP1214296B1 (es) |
| JP (1) | JP2003508515A (es) |
| KR (1) | KR100692232B1 (es) |
| CN (1) | CN1235877C (es) |
| AR (1) | AR035163A1 (es) |
| AT (1) | ATE262507T1 (es) |
| AU (1) | AU760061B2 (es) |
| BG (1) | BG65099B1 (es) |
| BR (1) | BR0013694A (es) |
| CA (1) | CA2381581A1 (es) |
| CO (1) | CO5190690A1 (es) |
| CZ (1) | CZ2002773A3 (es) |
| DE (1) | DE60009319T2 (es) |
| DK (1) | DK1214296T3 (es) |
| EE (1) | EE05080B1 (es) |
| ES (1) | ES2216940T3 (es) |
| HK (1) | HK1045496B (es) |
| HU (1) | HUP0202725A3 (es) |
| IL (2) | IL148111A0 (es) |
| IS (1) | IS2069B (es) |
| MX (1) | MXPA02002319A (es) |
| MY (1) | MY127036A (es) |
| NO (1) | NO20021040L (es) |
| NZ (1) | NZ517147A (es) |
| PL (1) | PL353887A1 (es) |
| PT (1) | PT1214296E (es) |
| RU (1) | RU2255085C2 (es) |
| SK (1) | SK286774B6 (es) |
| TR (1) | TR200200550T2 (es) |
| TW (1) | TW577867B (es) |
| WO (1) | WO2001017956A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003508509A (ja) | 1999-09-04 | 2003-03-04 | アストラゼネカ アクチボラグ | ピルビン酸デヒドロゲナーゼの阻害剤としてのアミド |
| GB0012012D0 (en) * | 2000-05-19 | 2000-07-05 | Astrazeneca Ab | Chemical compound |
| GB0120471D0 (en) * | 2001-08-23 | 2001-10-17 | Astrazeneca Ab | Chemical compounds |
| CN100562516C (zh) * | 2001-12-27 | 2009-11-25 | 第一制药株式会社 | β-淀粉样蛋白产生和分泌的抑制剂 |
| WO2012151448A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
| EA032007B1 (ru) | 2012-11-08 | 2019-03-29 | Аджиос Фармасьютикалз, Инк. | Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2 |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| SG11202001353PA (en) | 2017-08-15 | 2020-03-30 | Agios Pharmaceuticals Inc | Pyruvate kinase modulators and use thereof |
| CN109096186B (zh) * | 2018-09-29 | 2020-08-04 | 中南大学 | 一种2-芳磺酰基喹啉衍生物的合成方法 |
| CA3228249A1 (en) * | 2021-09-01 | 2023-03-09 | Maki YAMAKAWA | Nitrogen-containing tricyclic compound and pharmaceutical use thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0002309B1 (en) | 1977-10-12 | 1982-12-01 | Imperial Chemical Industries Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
| US4191775A (en) | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
| NZ197008A (en) | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
| AU8961382A (en) | 1981-11-06 | 1983-05-12 | Imperial Chemical Industries Plc | Amide derivatives |
| US4537618A (en) | 1982-05-26 | 1985-08-27 | Ciba Geigy Corporation | N-phenylsulfonyl-N'-pyrimidinylureas |
| EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
| GB8617653D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
| GB8617652D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
| GB9214120D0 (en) * | 1991-07-25 | 1992-08-12 | Ici Plc | Therapeutic amides |
| EP0539329A1 (de) | 1991-10-25 | 1993-04-28 | Ciba-Geigy Ag | Acetylen-Verbindungen, verwendbar als Leukotrien-Antagonisten |
| SE9103397D0 (sv) | 1991-11-18 | 1991-11-18 | Kabi Pharmacia Ab | Nya substituerade salicylsyror |
| IL105558A (en) | 1992-05-18 | 1998-04-05 | Zeneca Ltd | Tertiary carbinols with channel activity potassium process for their preparation and pharmaceutical preparations containing them |
| GB9305295D0 (en) * | 1993-03-15 | 1993-05-05 | Zeneca Ltd | Therapeutic compounds |
| GB9309716D0 (en) | 1993-05-12 | 1993-06-23 | Zeneca Ltd | Heterocyclic derivatives |
| GB9310095D0 (en) | 1993-05-17 | 1993-06-30 | Zeneca Ltd | Therapeutic compounds |
| GB9310069D0 (en) | 1993-05-17 | 1993-06-30 | Zeneca Ltd | Heterocyclic compounds |
| GB2278054A (en) | 1993-05-18 | 1994-11-23 | Zeneca Ltd | Compounds for the treatment of urinary incontinence |
| GB9505082D0 (en) | 1995-03-14 | 1995-05-03 | Zeneca Ltd | Medicament |
| GB9607458D0 (en) | 1996-04-10 | 1996-06-12 | Zeneca Ltd | Enzymatic process for stereoselective preparation of therapeutic amides |
| GB9804648D0 (en) * | 1998-03-06 | 1998-04-29 | Zeneca Ltd | Chemical compounds |
| GB9805520D0 (en) * | 1998-03-17 | 1998-05-13 | Zeneca Ltd | Chemical compounds |
| GB9811427D0 (en) | 1998-05-29 | 1998-07-22 | Zeneca Ltd | Chemical compounds |
-
2000
- 2000-08-30 AT AT00956672T patent/ATE262507T1/de not_active IP Right Cessation
- 2000-08-30 IL IL14811100A patent/IL148111A0/xx active IP Right Grant
- 2000-08-30 RU RU2002108508/04A patent/RU2255085C2/ru not_active IP Right Cessation
- 2000-08-30 HU HU0202725A patent/HUP0202725A3/hu unknown
- 2000-08-30 KR KR1020027002841A patent/KR100692232B1/ko not_active IP Right Cessation
- 2000-08-30 JP JP2001521703A patent/JP2003508515A/ja active Pending
- 2000-08-30 WO PCT/GB2000/003314 patent/WO2001017956A1/en active Application Filing
- 2000-08-30 TR TR2002/00550T patent/TR200200550T2/xx unknown
- 2000-08-30 PT PT00956672T patent/PT1214296E/pt unknown
- 2000-08-30 DK DK00956672T patent/DK1214296T3/da active
- 2000-08-30 CA CA002381581A patent/CA2381581A1/en not_active Abandoned
- 2000-08-30 AU AU68543/00A patent/AU760061B2/en not_active Ceased
- 2000-08-30 ES ES00956672T patent/ES2216940T3/es not_active Expired - Lifetime
- 2000-08-30 MX MXPA02002319A patent/MXPA02002319A/es active IP Right Grant
- 2000-08-30 MY MYPI20004037 patent/MY127036A/en unknown
- 2000-08-30 PL PL00353887A patent/PL353887A1/xx not_active Application Discontinuation
- 2000-08-30 BR BR0013694-8A patent/BR0013694A/pt not_active Application Discontinuation
- 2000-08-30 SK SK300-2002A patent/SK286774B6/sk not_active IP Right Cessation
- 2000-08-30 CN CNB008152446A patent/CN1235877C/zh not_active Expired - Fee Related
- 2000-08-30 NZ NZ517147A patent/NZ517147A/en unknown
- 2000-08-30 EE EEP200200113A patent/EE05080B1/xx not_active IP Right Cessation
- 2000-08-30 DE DE60009319T patent/DE60009319T2/de not_active Expired - Fee Related
- 2000-08-30 EP EP00956672A patent/EP1214296B1/en not_active Expired - Lifetime
- 2000-08-30 CZ CZ2002773A patent/CZ2002773A3/cs unknown
- 2000-08-30 US US10/069,994 patent/US6689909B1/en not_active Expired - Fee Related
- 2000-09-01 CO CO00065992A patent/CO5190690A1/es not_active Application Discontinuation
- 2000-09-04 AR ARP000104623A patent/AR035163A1/es unknown
- 2000-09-04 TW TW089118053A patent/TW577867B/zh not_active IP Right Cessation
-
2002
- 2002-02-11 IL IL148111A patent/IL148111A/en not_active IP Right Cessation
- 2002-02-26 IS IS6285A patent/IS2069B/xx unknown
- 2002-03-01 NO NO20021040A patent/NO20021040L/no not_active Application Discontinuation
- 2002-03-14 BG BG106520A patent/BG65099B1/bg active Active
- 2002-09-25 HK HK02107004.7A patent/HK1045496B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR107377A2 (es) | Compuestos derivados de tetrahidroquinolina | |
| PE20000334A1 (es) | Compuestos para el tratamiento de la isquemia | |
| KR950704330A (ko) | 면역억제제로서의 라파마이신 카보네이트 에스테르(Rapamycin carbonate esters as immunosuppressant agents) | |
| RU2368608C2 (ru) | Производные пиперидина в качестве модуляторов хемокинового рецептора ccr5 | |
| AR067663A1 (es) | Derivados heterociclicos de etiloxi amidas, composiciones que los comprenden y usos de los mismos en agricultura u horticultura, como agentes antifungicos. | |
| AR036114A1 (es) | Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes | |
| PE20010130A1 (es) | Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR035163A1 (es) | Compuesto derivado de n-fenil-2-hidroxi-2-metil-3,3,3-trifluoropropanamida, composicion farmaceutica, uso en la fabricacion de un medicamento y proceso para su preparacion | |
| PE20091573A1 (es) | Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| PE20010963A1 (es) | OXAZOLIDINONAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR DE COAGULACION Xa | |
| RU2354655C2 (ru) | Ингибиторы сомт | |
| RU2008127257A (ru) | Тризамещенные производные хиназолинона в качестве ваниллоидных антагонистов | |
| AR039226A2 (es) | Compuestos utiles como intermediarios de preparacion y procedimientos | |
| PE20020759A1 (es) | Derivados de bencilamina con base prolina como inhibidores de trombina | |
| AR072793A1 (es) | Compuestos de aril isoxazol con actividades antitumorales | |
| RU2010101004A (ru) | Новые микробиоциды |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |